Partner News | Published: Thursday, July 10, 2025
egnite, Inc., a leading cardiovascular digital health company, announced the launch of the CardioCare Research Suite, a significant expansion of its flagship platform designed to streamline and enhance patient identification for clinical trials.
The Research Suite supports ten landmark clinical trials in structural heart and heart failure care, including AIM-HIGHer, ALT-FLOW II, APOLLO, ARTIST, CLASP IIF, CLASP II TR, CORCINCH-HF, EMPOWER, ENCIRCLE and PROGRESS.
This expansion addresses a long-standing challenge in clinical research, ensuring the right patients are surfaced at the right time for trial consideration. Through the use of artificial intelligence (AI) and natural language processing to analyze both structured and unstructured hospital data, the CardioCare Research Suite empowers hospitals to expand access to novel therapies and reduce the operational burden on research teams.
Early adopters of the Research Suite have reported meaningful results:
“Since our inception, ambitious programs have expressed a desire to leverage the CardioCare platform to move from passive intake to proactive identification of clinical trial patients,” said Kahla Verhoef, chief operating officer at egnite. “The Research Suite is a direct response to that need, empowering research teams to efficiently surface eligible patients from complex data, align with evolving trial criteria, and engage physicians with precision and confidence.”
egnite’s CardioCare Research Suite is now available to all partner hospitals using the CardioCare platform. With the ability to leverage AI across structured and unstructured data, the platform uniquely equips research teams to accelerate enrollment and drive clinical innovation forward.
By continuing to use our site, you agree to our Cookie Policy, Privacy Policy and Terms of Use.